Q-omics provides the consensus-scored CLDN11 profile across patient tissues and cancer cell-line models. CLDN11 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CLDN11 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, CLDN11 RNA expression shows 23,336 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where CLDN11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLDN11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLDN11 survival associations across molecular data types. CLDN11 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLDN11 RNA expression–survival associations across cancer types. High CLDN11 expression shows unfavorable associations in KIRP, KIRC, UCEC and UVM, but favorable associations in BRCA and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CLDN11 RNA expression.
This table summarizes CLDN11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CLDN11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLDN11 shows lower tumor expression in KIRC, COAD, LUAD, HNSC, KICH and BRCA. The KIRC box plot shows higher CLDN11 RNA expression in normal versus tumor tissue (log2 FC = −1.712, t-test p < 0.001).
This table shows molecular features associated with CLDN11 in patient tissues and cancer cell lines. In patient samples, CLDN11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLDN11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Myeloma.
